Evidence map›Paper›PMID 39448507›Full record

ArticleJournal of general internal medicine2025

"We're Not Gonna Aid You in Shooting Up": Stigma's Relationship to Harm Reduction in People Who Inject Drugs.

Rachel Weger, Nathan Weinstock, Raagini Jawa, J Deanna Wilson

Abstract read
In one paragraph

Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rachel WegerUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, USA. rachel.weger@pitt.edu.ORCID 0000-0003-0897-9658
Nathan WeinstockCenter for Research in Healthcare, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Raagini JawaUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J Deanna WilsonDepartment of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Funding

Penn Mental Health AIDS Research CenterP30MH097488 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Knashawn Hodge Morales · 2013 to 2026
$23.5M
THRIVE: Teaching Health promotion and Resilience in Varied Environments: a peer-led intervention following hospital dischargeR01DA057633 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jacqueline Deanna Wilson · 2022 to 2026
$3.8M
Treatment of Opioid Use Disorder in Young Adults Hospitalized with Infectious Complications of Injection Opioid UseK23DA048987 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WILSON, JACQUELINE DEANNA · 2020 to 2022
$570k
NIDA NIH HHS K23 DA048987NIDA NIH HHS R01 DA057633NIH HHS K23DA048987NIH HHS R01DA057633NIMH NIH HHS P30 MH097488
6 · The paper itself

Abstract

backgroundHarm reduction, when applied to drug use, prioritizes improving patient-centered health outcomes and reducing drug-related harm. In order for harm reduction strategies to be adopted by people who inject drugs (PWID), they need to be promoted, accessible, and accepted in that population and the community-at-large. While PWID face stigma at multiple levels, less is known about how stigma influences uptake and acceptance of harm reduction services and strategies among PWID.

objectiveWe aim to characterize the stigmatizing experiences PWID have had related to harm reduction and the role of stigma in influencing their acceptance and adoption of harm reduction services and strategies.

designA qualitative study using in-person, semi-structured interviews.

participantsWe recruited hospitalized participants, age 18 and over, with a history of injection drug use. APPROACH: We developed an interview guide asking about various aspects of stigma and participants' experiences with naloxone, syringe service programs, fentanyl test strips, HIV and hepatitis C testing, and any other harm reduction strategies. Key themes were generated using a thematic analysis. We reached thematic saturation at 16 participants. KEY

resultsPWID reported multi-level stigma related to harm reduction from themselves, the public, the healthcare system, and the legal and carceral systems. Themes were grouped into four main categories: internalized, interpersonal, intervention, and structural stigma. Stigma across all of these domains negatively impacted the ability of PWID to access harm reduction resources. Positive, non-stigmatizing experiences from others, such as syringe service programs and peer navigators, countered historically negative experiences and promoted greater education and comfort about using harm reduction resources among PWID.

conclusionsTo expand the reach of harm reduction services, it is critical to develop interventions that can reduce the stigma against PWID and harm reduction.

Indexed as

Harm ReductionSocial StigmaSubstance Abuse, IntravenousAdultFemaleHumansMaleMiddle AgedNeedle-Exchange ProgramsPatient Acceptance of Health CareQualitative ResearchYoung Adultharm reductioninjection drug usestigma

Identifiers

PMID39448507
PMCPMC12463774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.